🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of BHV-1400 in IgA Nephropathy

RecruitingPhase 1Ages 18 Years - 65 YearsAllBiohaven Therapeutics Ltd.
NCT07054684 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
💊

What it tests

  • BHV-1400
📍

Where

15 sites
Site-001
Farmington, United States
Site-003
Miami Lakes, United States
Site-011
Miami Lakes, United States
Site-013
Orlando, United States
Site-005
Pembroke Pines, United States
Site-008
Lawrenceville, United States
Site-009
Hinsdale, United States
Site-012
Indianapolis, United States

…and 7 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy